Effect of Oral Magnesium Supplementation on Type II Diabetes Mellitus Guided by Serum Ionized Magnesium Level
Type 2 Diabetes, Magnesium Disorder
About this trial
This is an interventional supportive care trial for Type 2 Diabetes
Eligibility Criteria
Inclusion Criteria: Adults (≥18 years old). Treated with oral hypoglycemic agents (OHA) ± insulin regimen. Had HbA1c ≥ 7% in the last 3 months Exclusion Criteria: HbA1c of < 7%. Fully dependent patients as per clinical frailty score End stage renal disease (creatinine clearances (CrCl) at < 10ml/min) With neuromuscular disease With active solid or hematological malignancies. With cognitive disorders. With the following regular medications (baloxavir marboxil, calcium/sodium polystyrene sulfate, raltegravir, or unithiol) due to X category drug-drug interaction (contraindicated combinations) when given concurrently Mg oxide
Sites / Locations
Arms of the Study
Arm 1
Arm 2
Active Comparator
Placebo Comparator
Interventional group (Mg oxide supplementation):
Control group (placebo tablets)
Interventional group (Mg oxide supplementation): Patients in this group will receive Mg oxide tablet 500 mg (302 mg elemental), with a dosage regimen of 1 table once daily as per the recommended range of the daily dose (from 250 to 500 mg elemental) (29, 31, 41, 45). Tablets should be taken with food and 2 hrs. apart from other medications for 12 consecutive months.
Control group (placebo tablets): Patients in this group will receive placebo tablets labeled as 500 mg (302 mg elemental), with a dosage regimen of 1 tablet once daily. Tablets should be taken with food and 2 hrs. apart from other medications for 12 consecutive months.